NCT01826786View on ClinicalTrials.gov

The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-42165279 (100 mg)

JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.

DRUG

Placebo

Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.

Trial Locations (1)

Unknown

La Jolla

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01826786 - The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter